clinical pharmacokinetics of therapeutic monoclonal antibodies
· Monoclonal antibodies mAbs are widely used therapeutic agents in hematology and oncology Despite the therapeutic benefit these antibodies either do not have the desired clinical efficacy or have to be co-administered with traditional chemotherapy These shortcomings of mAbs led to efforts to enhance the therapeutic benefit of mAbs by modifications mainly by forming a conjugate
Lieu : 8600 Rockville Pike Bethesda MD
DOI: 102165/11531280-000000000-00000 Corpus ID: 23086473 Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies @article{Keizer2010ClinicalPO title={Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies} author={R Keizer and A Huitema and J, Schellens and J, Beijnen}, journal={Clinical Pharmacokinetics}, year={2010}, volume={49}, pages={493-507} }
Clinical Pharmacokinetics of Therapeutic Monoclonal
· Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates decision making during drug discovery, and increases the probability of success for early clinical …
Tutorial on Monoclonal Antibody Pharmacokinetics and Its
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors CPT Pharmacometrics Syst Pharmacol 2017 Jan;61:49-57 doi: 10,1002/psp4,12139 PubMed PMID: 27863186; PubMed Central PMCID: PMC5270291 10: Gibbs JP Doshi S, Kuchimanchi M, Grover A, Emery MG, Dodds MG, Gibbs MA, Somaratne R, Wasserman SM, Blom D
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics PK in the context of drug development Topics covered include an overview of antibody development PK characteristics and the application of antibody PK/pharmacodynamics PD in research and development decision-making, We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal
Pharmacokinetics and pharmacodynamics of therapeutic
clinical pharmacokinetics of therapeutic monoclonal antibodies
Monoclonal antibodies mAbs have dramatically improved clinical outcomes for inflammatory and malignant diseases The elimination route of mAbs is cellular uptake by nonspecific pinocytosis or receptor-mediated endocytosis followed by proteolytic degradation which is protected by neonatal Fc-receptor or mediated by antigenic target There is a wide-interindividual variability in mAbs exposure due to target burden and other factors affecting unique their pharmacokinetics …
Physiologically-based pharmacokinetic modeling to predict
· General oncology therapeutic antibody pharmacokinetics Therapeutic monoclonal antibody mAb therapy has exhibited remarkable success over the past decade: not only did mAb-based therapeutics account for four of the top five best-selling drugs in 2018 but the Nobel Prize in Physiology and Medicine was awarded that same year for the discovery of the mAb-based cancer immunotherapy agent ipilimumab [12],
Lieu : 8600 Rockville Pike, Bethesda, MD
Pharmacokinetic and pharmacodynamic study of a clinically
· Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies 1 Monoclonal Antibodies and Antibody Fragments Each chain contains a constant and a variable part The antigen-binding 2, Administration Route and Absorption, Monoclonal antibodies are administered parenterally — …
Cited by : 534
Clinical pharmacokinetics of therapeutic monoclonal
· Monoclonal antibodies mAbs have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications with currently more than 40 mAbs approved by the US Food and Drug Administration and several dozens more in clinical development This tutorial will review major drug disposition processes relevant for mAbs and will highlight product‐specific and patient‐specific factors that modulate their pharmacokinetic …
Lieu : 8600 Rockville Pike Bethesda MD
Population pharmacokinetics of therapeutic monoclonal
Monoclonal antibodies mAbs have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity Their pharmacokinetic properties differ markedly from those of non-antibody-type drugs and these properties can have important clinical implications mAbs are administered intravenously, intramuscularly or subcutaneously,
Pharmacokinetics of Monoclonal Antibodies
Clinical pharmacokinetics of therapeutic monoclonal antibodies
Monoclonal antibodies mAbs have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity Their pharmacokinetic properties differ markedly from those of non-antibody-type drugs and these properties can have important clinical implications mAbs are administered intravenously, intramuscularly or subcutaneously, Oral administration is precluded by the …
Cited by : 534
Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
A growing number of population pharmacokinetic analyses of therapeutic monoclonal antibodies mAbs have been published in the scientific literature The aims of this article are to summarize the findings from these studies and to relate the findings to the general pharmacokinetic and structural characteristics of therapeutic mAbs, A two-compartment model was used in the majority of the population analyses to describe the …
Therapeutic drug monitoring of monoclonal antibodies
Pharmacokinetic and pharmacodynamic study of a clinically effective anti-CD2 monoclonal antibody Sellberg F 1 Berglund D 1 Binder C 1 Hope J 2 Fontenot J 3 Griesemer A 4, Sykes M 4, Sachs DH 4, Berglund E 4 5, Author information: 1Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala